Merck stock after-hours at EUR 125.35: plus 0.86 percent versus Lang & Schwarz prior close

Merck stock was at EUR 125.35 after-hours at 8:14 p.m. CEST on October 6, 2026, up 0.86 percent versus the Lang & Schwarz prior close of EUR 124.28. The quote was reported by Lang & Schwarz.

Merck stock after-hours

Merck’s after-hours price was EUR 125.35 at 8:14 p.m. CEST. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Merck stock.

License agreement for investigational cancer drug

In a release dated September 28, Merck said it had entered an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, an investigational preclinical oral KRAS G12D inhibitor. Under the agreement, Merck obtained worldwide rights to develop, manufacture and commercialize SPR2015. SciBrunch is to receive an upfront payment of USD 400 million and may receive milestone payments; the transaction’s potential aggregate value, including the upfront payment, is USD 2.13 billion. Merck said the transaction had closed and that it would record a pre-tax charge of USD 400 million, or approximately USD 0.13 per share, in third-quarter 2026 GAAP and non-GAAP results. Merck said SPR2015 is an investigational preclinical therapy.

Third-quarter earnings call scheduled

Merck said on October 1 that it will hold its third-quarter 2026 sales and earnings conference call at 9:00 a.m. ET on October 29. The company said executives will provide an overview of the quarter’s performance, with a webcast, replay, sales and earnings release, supplemental financial disclosures and presentation slides to be available through Merck. Merck identified the company as Merck (NYSE: MRK).